Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
4basebio UK Societas (GB:4BB)
LSE:4BB
Holding GB:4BB?
Track your performance easily
4BB Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range492.00p - 1,820.00p
Previous Close1,400p
Volume224.00
Average Volume (3M)1.03K
Market Cap
£179.35M
Enterprise Value174.76M
Total Cash (Recent Filing)£4.59M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Sep 27, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding12,319,473
10 Day Avg. Volume615
30 Day Avg. Volume1,029
Standard Deviation0.13
R-Squared0.12
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)5000.00
Price to Sales (P/S)487.21
Price to Cash Flow (P/CF)-28.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
4basebio UK Societas News
PremiumCompany Announcements
4basebio Announces Major Investment and Share Reshuffle
PremiumCompany Announcements
4basebio Forms Key Advisory Board and Appoints New COO
PremiumCompany Announcements
4basebio PLC Raises £69.4M for Expansion
PremiumCompany Announcements
4basebio PLC Unveils Employee Share Incentive Plan
PremiumCompany Announcements
Significant Shareholding Change in 4basebio UKPremiumCompany Announcements
4basebio UK Societas Shareholding Shift NotedPremiumCompany Announcements
4basebio PLC Announces Ownership Threshold ChangePremiumCompany Announcements
Deutsche Balaton Adjusts Stake in 4basebio PLCOptions Prices
Currently, No data available
---
Ownership Overview
14.32% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
85.68% Public Companies and
Individual Investors
4BB FAQ
What was 4basebio UK Societas’s price range in the past 12 months?
4basebio UK Societas lowest share price was 492.00p and its highest was 1820.00p in the past 12 months.
What is 4basebio UK Societas’s market cap?
Currently, no data Available
When is 4basebio UK Societas’s upcoming earnings report date?
4basebio UK Societas’s upcoming earnings report date is Sep 27, 2024 which is in 7 days.
How were 4basebio UK Societas’s earnings last quarter?
4basebio UK Societas released its earnings results on May 08, 2024. The company reported -0.334p earnings per share for the quarter, missing the consensus estimate of N/A by -0.334p.
Is 4basebio UK Societas overvalued?
According to Wall Street analysts 4basebio UK Societas’s price is currently Overvalued.
Does 4basebio UK Societas pay dividends?
4basebio UK Societas does not currently pay dividends.
What is 4basebio UK Societas’s EPS estimate?
4basebio UK Societas’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 4basebio UK Societas have?
4basebio UK Societas has 12,810,728 shares outstanding.
What happened to 4basebio UK Societas’s price movement after its last earnings report?
4basebio UK Societas reported an EPS of -0.334p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.926%.
Which hedge fund is a major shareholder of 4basebio UK Societas?
Currently, no hedge funds are holding shares in GB:4BB
---
4basebio UK Societas Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.50%
12-Months-Change
Fundamentals
Return on Equity
-231.29%
Trailing 12-Months
Asset Growth
1.99%
Trailing 12-Months
Company Description
4basebio UK Societas
4basebio UK Societas is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use. The principal objective of 4bb is to validate and scale its DNA synthesis process to manufacture Good Manufacturing Practice grade DNA, suitable for use in gene therapies and DNA vaccines.
---
Technical Analysis
---